Specifically, CALR expression was significantly increased in CT26 cells (murine colorectal cancer) that responded to anti-CTLA and anti-PD-1 treatment, and CALR expression was obviously increased in EMT6 cells (murine breast cancer) that responded to anti-PD-1 treatment. The gene discussed is CALR; the disease is breast cancer.